Fox04

Beskrivelse

FOXO4 (often referred to as FOXO4-DRI or FOXO4-p53 interfering peptide) is a cell-penetrating synthetic D-retro-inverso peptide engineered to selectively induce apoptosis in senescent cells. It works by competitively binding to the forkhead box O4 (FOXO4) transcription factor, preventing its interaction with p53 in the nucleus of senescent cells. This disruption releases p53 to trigger the intrinsic apoptotic pathway specifically in cells that have entered irreversible senescence—characterized by permanent cell cycle arrest, secretion of pro-inflammatory and tissue-disrupting factors (the senescence-associated secretory phenotype or SASP), and resistance to normal cell death signals. By eliminating these dysfunctional “zombie” cells, FOXO4 aims to reduce chronic low-grade inflammation (“inflammaging”), restore tissue homeostasis, improve organ function, and mitigate age-related decline. Landmark preclinical studies (notably the 2017 Nature publication by Baar et al.) demonstrated that FOXO4-DRI treatment in aged mice and fast-aging mouse models led to significant clearance of senescent cells, reversal of age-related phenotypes (including fur density, kidney function, physical endurance, and behavioral performance), reduced SASP markers, and extension of healthspan without broadly affecting healthy cells. Subsequent research has explored its potential in models of atherosclerosis, osteoarthritis, pulmonary fibrosis, liver disease, and frailty. In longevity and biohacking communities, FOXO4-DRI is one of the most discussed targeted senolytics, typically researched via subcutaneous or intravenous injection (anecdotal/research doses often in the range of 5–25 mg/kg body weight, administered in cycles of several consecutive days followed by weeks off). Users report subjective improvements in energy, joint comfort, skin quality, and recovery, though human data remains extremely limited—primarily extrapolated from animal models and small observational reports. As of 2026, FOXO4-DRI is not FDA-approved for any therapeutic, anti-aging, disease treatment, or wellness use—it remains a strictly investigational research peptide with no large-scale human clinical trials completed or ongoing for systemic senolytic indications. Safety profile in animal studies appears favorable with no major off-target toxicity at effective doses, but human risks are largely unknown and may include injection-site reactions, transient inflammation flares during senescent cell clearance, potential immune responses to the peptide, or unforeseen effects on p53-dependent processes in healthy tissues. It is prohibited by WADA for athletes and should never be used without strict supervision from a qualified healthcare provider experienced in senotherapeutics or peptides, as self-administration carries significant risks of contamination from unregulated sources, incorrect dosing, serious adverse reactions, or legal issues. Prioritize evidence-based longevity strategies—exercise, caloric/nutrient optimization, sleep, stress management, and approved interventions—over unapproved research compounds. Consult a professional to evaluate suitability, and stay informed on emerging clinical trial data or regulatory developments. FOXO4-DRI is not a substitute for proven medical treatments or lifestyle practices.